Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

It is the ninth Humira biosimilar approved by the FDA and the fourth to receive interchangeability status. The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the ...

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...

AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition. Humira still dominated 96% of ...

It's official! UnitedHealth's Optum Rx pharmacy benefit manager unit will not be a haven for employers and workers who love Humira. The PBM told sponsors of commercial plans in August that it ...

MedImpact Healthcare Systems, an independent provider of health solutions, technology and pharmacy benefit services, is expanding access to Humira biosimilars, Simlandi and adalimumab-adaz ...

It is intravenously administered, allowing for flexible dosing to reach ideal efficacy Despite AbbVie’s Humira being the only approved biologic in moderate-to-severe hidradenitis suppurativa (HS ...

(Reuters) - AbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether ...

Evernorth's Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs, the company announced Thursday. Accredo is the specialty pharmacy segment within Evernorth ...

Starting April 1, 2024, Hyrimoz and an unbranded version of Humira manufactured by Sandoz will be covered across all CVS formularies. CVS Health has announced that it will remove AbbVie’s blockbuster ...

CVS also announced that AbbVie and CVS-owned company Cordavis, which launched in August, will produce a co-branded version of Humira that will be made available to customers in the second quarter ...